STRO

SUTRO BIOPHARMA, INC. STRO

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,813 of 2,925

Why it scores 15Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$9.84M

Quarter to Jun 30

Net income

$-38.53M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$545.67M total
PERCEPTIVE ADVISORS LLC
$43.32M+82.4%
BVF INC/IL
$41.56M0.0%
Affinity Asset Advisors, LLC
$38.93M+9.6%
BlackRock, Inc.
$37.27M+382.5%
Samsara BioCapital, LLC
$35.29M0.0%
Kynam Capital Management, LP
$28.97M0.0%
ORBIMED ADVISORS LLC
$24.70M-7.1%
BALYASNY ASSET MANAGEMENT L.P.
$23.61M+52.7%
VANGUARD CAPITAL MANAGEMENT LLC
$23.05M-3.6%
EVENTIDE ASSET MANAGEMENT, LLC
$19.43M-18.2%
Velan Capital Investment Management LP
$17.00M0.0%
Woodline Partners LP
$15.21M+0.1%
ADAR1 Capital Management, LLC
$13.41M-23.0%
GEODE CAPITAL MANAGEMENT, LLC
$12.94M+127.4%
ACADIAN ASSET MANAGEMENT LLC
$12.40M+11.3%
MILLENNIUM MANAGEMENT LLC
$12.15M+74.0%
STATE STREET CORP
$10.16M+487.1%
Merck & Co., Inc.
$9.04M0.0%
ACUTA CAPITAL PARTNERS, LLC
$8.97M+0.3%
AMERIPRISE FINANCIAL INC
$8.12MNew
Point72 Asset Management, L.P.
$7.90M-65.6%
KVP Capital Advisors, LP
$7.52M0.0%
UBS Group AG
$6.92M-46.9%
TWO SIGMA INVESTMENTS, LP
$6.70M+209.5%
VANGUARD PORTFOLIO MANAGEMENT LLC
$6.56MNew
See all 100 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/STRO

Earnings Per Share

13fpro.ai/company/STRO

Loading ratio trend…

STRO key financials by period

Reported revenue, net income and operating margin by fiscal year, from SUTRO BIOPHARMA, INC.'s annual filings on SEC EDGAR.

SUTRO BIOPHARMA, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$102.5M$-191.1M-154.5%
FY 2024$62.0M$-227.5M—
FY 2023$153.7M$-106.8M-58.1%
FY 2022$67.8M$-119.2M-190.3%
FY 2021$61.9M$-105.5M-159.2%
FY 2020$42.7M$-32.1M-166.3%
Source: STRO filings on SEC EDGAR →

Companies similar to STRO

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

STRO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About SUTRO BIOPHARMA, INC. (STRO): stock profile, AI score and financials

SUTRO BIOPHARMA, INC. (STRO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STRO at 15.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,813 of 2,925 stocks — the bottom half of the AI-ranked universe. STRO scores in the top quartile across institutional flow (92.6). Areas of concern include balance sheet strength (1.6) and free cash flow (3.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), SUTRO BIOPHARMA, INC. reports quarterly revenue of $9.8M, net income of $-38.5M. STRO trades on the Nasdaq exchange and files with the SEC under CIK 1382101. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SUTRO BIOPHARMA, INC. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1382101 →